Needham & Company LLC Reiterates Hold Rating for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Monday, TipRanks reports.

Several other brokerages also recently weighed in on GILD. Goldman Sachs Group set a $27.00 price target on shares of Melco Resorts & Entertainment and gave the company a “buy” rating in a report on Tuesday, May 28th. Morgan Stanley set a $70.00 price objective on shares of Edison International and gave the company a “hold” rating in a research report on Monday. Zacks Investment Research cut shares of Hersha Hospitality Trust from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. Evercore ISI reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, May 17th. Finally, BMO Capital Markets set a $76.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seventeen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $80.99.

Shares of Gilead Sciences stock traded down $0.02 during trading on Monday, hitting $66.92. The company’s stock had a trading volume of 4,179,362 shares, compared to its average volume of 6,241,528. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. The business’s fifty day moving average price is $66.65. The firm has a market capitalization of $85.45 billion, a P/E ratio of 10.88, a PEG ratio of 3.18 and a beta of 1.12. Gilead Sciences has a 52 week low of $60.32 and a 52 week high of $79.61.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.53 by $0.23. The business had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. Gilead Sciences’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the business earned $1.48 EPS. As a group, equities research analysts anticipate that Gilead Sciences will post 6.6 EPS for the current fiscal year.

In other Gilead Sciences news, Director John Francis Cogan sold 2,868 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $64.89, for a total transaction of $186,104.52. Following the transaction, the director now owns 57,728 shares in the company, valued at $3,745,969.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the transaction, the executive vice president now owns 27,198 shares in the company, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. Insiders sold 11,384 shares of company stock worth $755,002 in the last 90 days. 0.20% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. Nomura Asset Management Co. Ltd. boosted its stake in Gilead Sciences by 18.7% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 504,175 shares of the biopharmaceutical company’s stock worth $31,536,000 after purchasing an additional 79,286 shares during the period. Bessemer Group Inc. raised its holdings in Gilead Sciences by 21.2% in the 4th quarter. Bessemer Group Inc. now owns 37,104 shares of the biopharmaceutical company’s stock valued at $2,322,000 after acquiring an additional 6,487 shares during the period. Gluskin Sheff & Assoc Inc. bought a new position in Gilead Sciences in the 4th quarter valued at about $10,978,000. Aptus Capital Advisors LLC bought a new position in Gilead Sciences in the 4th quarter valued at about $1,372,000. Finally, Korea Investment CORP raised its holdings in Gilead Sciences by 0.9% in the 4th quarter. Korea Investment CORP now owns 758,767 shares of the biopharmaceutical company’s stock valued at $47,461,000 after acquiring an additional 6,900 shares during the period. Institutional investors and hedge funds own 78.69% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Why is the Consumer Price Index (CPI) important?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.